Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc develops clinical-stage medicines based on its proprietary bicyclic peptide, or Bicycle®, technology. Its updates center on oncology programs using fully synthetic constrained peptides, including nuzefatide pevedotin, a Bicycle Drug Conjugate targeting EphA2; zelenectide pevedotin, a Bicycle Drug Conjugate targeting Nectin-4; BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist targeting Nectin-4 and CD137; and Bicycle Radioconjugates for radiopharmaceutical use.
Recurring news includes clinical and preclinical data presentations, oncology pipeline updates, financial results, leadership changes, and collaborations that support radioisotope and radiopharmaceutical supply. Company announcements also discuss work with partners in additional therapeutic areas and the structure of its U.K. and U.S. operations.
Bicycle Therapeutics (NASDAQ: BCYC) reported third-quarter 2022 financial results, highlighting clinical progress across its pipeline. The company anticipates completing enrollment in the BT5528 initial dose expansion cohorts by Q4. A significant $10 million option fee from Genentech enhances their financial position, with cash and equivalents at $361.5 million, providing a runway into 2025. However, R&D expenses rose to $22.8 million, impacting net loss, which widened to $28.3 million or $(0.96) per share compared to $(0.59) in Q3 2021.
Ambi Robotics has secured $32 million in funding, aiming to enhance its AI-powered parcel sorting systems due to rising demand, especially during the holiday season. Existing investors, including Tiger Global and Bow Capital, are joined by Ahren and strategic partner Pitney Bowes (NYSE:PBI). This funding follows a previous $23 million deployment expansion with Pitney Bowes, facilitating more than 80 installations of AmbiSort A-Series systems. The technology promises to boost warehouse efficiency, with each system increasing throughput to over 1,200 items per hour.
Bicycle Therapeutics plc (NASDAQ: BCYC) has announced the publication of preclinical data for BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, in the Journal of Medicinal Chemistry. This study, alongside previous research, supports BT8009's development for treating Nectin-4 expressing tumors, which are prevalent in various solid cancers. The company is currently evaluating BT8009 in a Phase I/II clinical trial. Bicycle's innovative Bicycle technology aims to create effective therapies for underserved cancer indications.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced the publication of preclinical data for BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, in Molecular Cancer Therapeutics. The article details its efficacy in killing solid tumor cells, with significant tumor regression observed in various models. The results follow positive interim findings from its Phase I trial, which suggest BT8009's potential for treating solid tumors effectively. Additional clinical data is expected later this year, underscoring the drug’s promising development trajectory.
Bicycle Therapeutics (NASDAQ: BCYC) announced promising Phase I results for BT5528, targeting EphA2 in patients with advanced solid tumors. The study showed anti-tumor activity, particularly in ovarian and urothelial cancers, with an overall response rate of 22% for ovarian patients and 67% for urothelial patients. The safety profile appears favorable, with low incidence of serious side effects. Enrollment in the expansion cohorts at a recommended dose of 6.5mg/m2 every other week continues. A conference call will be held today at 8:30 a.m. ET.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced management's participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 10:00 a.m. ET. The event will be accessible via a live webcast on Bicycle's website, with an archived replay available for 90 days afterwards. Bicycle Therapeutics specializes in developing innovative therapeutics utilizing its proprietary bicyclic peptide technology, focusing on drug candidates for underserved diseases.
Bicycle Therapeutics (NASDAQ: BCYC) reported continued clinical progress, including dosing the first patient in the Phase I/II study of BT5528. The expansion of collaboration with Genentech triggered a $10 million payment expected in Q3 2022. As of June 30, 2022, the company had cash and equivalents of $372.8 million, providing financial runway into 2025. R&D expenses rose to $19.9 million from $11.7 million year-over-year, while G&A expenses increased to $11.8 million. Net loss for the quarter was $26.8 million, or $(0.90) per share, compared to a loss of $17.9 million a year earlier.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced the publication of an article in Bioconjugate Chemistry regarding the use of tris-Gold complexes to enhance the chemical diversity of its proprietary Bicycle peptides. The research showcases a method for constructing constrained Bicycle peptides, which may be beneficial for future targets. CEO Kevin Lee highlighted this publication as a sign of the company's robust research capabilities. Bicycle continues clinical trials for several candidates, including BT5528 and BT8009, targeting important tumor antigens.
Circle Pharma has appointed Paul Park as its Chief Business Officer to advance its lead program, an orally bioavailable Cyclin A inhibitor, towards clinical trials. Park brings extensive experience from previous roles at Ionis Pharmaceuticals and Amgen, where he led significant business transactions. The company aims to leverage its macrocycle platform to expand its pipeline, focusing on oncology therapeutics targeting cyclin proteins, which play a critical role in cancer cell regulation. Circle’s approach addresses unmet clinical needs in serious diseases.
Bicycle Therapeutics (NASDAQ: BCYC) reported the publication of preclinical data on BT7480, a novel tumor-targeted immune cell agonist, in the Journal of Medicinal Chemistry. BT7480 targets Nectin-4 and activates CD137, demonstrating unique properties such as small size and potent immune activation. This molecule is currently in Phase I development with ongoing dose escalation. Bicycle aims to advance its pipeline with BT7480 as a potential clinical candidate, leveraging its proprietary Bicycle technology to enhance anti-tumor immunity.